Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) has been successfully used to treat many high-risk hematological malignancies and marrow failure syndromes. The best results with allogeneic HSCT have been obtained in patients receiving allograft from HLA-matched siblings. As the chance of finding a HLA genotypically identical sibling donor is only 25%, much attention has been focused on the use of alternative donors, either from matched unrelated volunteer adult donors, umbilical cord blood or partially matched related donors. Despite the expansion of worldwide unrelated donor registries that have markedly improved the chances of finding a donor for many patients, 1 the application of transplantation using unrelated adult volunteer donors has been limited by some major obstacles, which include (i) the wide range of finding a phenotypically matched unrelated donor by chance, from 60 to 70% for Caucasians to under 10% for ethnic minorities 2, 3 and (ii) the cumbersome process of identifying, typing and harvesting an unrelated donor, with the median time interval between initiation of a search and the donation of marrow of about 4 months, 4 rendering this option less viable for patients who urgently need transplantation, such as those with acute leukemia. This is because many such patients do not survive the long waiting period until a suitable donor can be found. Moreover, allogeneic transplant using the matched unrelated donor is associated with a high transplant-related mortality (30-40%) and high long-term morbidity. [5] [6] [7] [8] [9] Umbilical cord blood, on the other hand, may overcome some of these limitations due to easy procurement, the absence of risk for donors, potential reduced risk of GVHD, 10 and less stringent criteria for HLA matching for donor-recipient selection. However, engraftment remains a major concern due to the low number of progenitor cells contained in an umbilical cord blood unit, especially in the adult population. Moreover, delayed neutrophil recovery and TRM remain the main obstacles to successful UCB transplantation, particularly in patients receiving myeloablative preparative regimens. 11, 12 The use of hematopoietic stem cells from relatives who are partially matched for HLA provides some advantages for patients lacking HLA-matched sibling donors or fully matched unrelated donors. Virtually all patients have at least one HLA-partially matched family member, parent, sibling or child, who is immediately available to serve as a donor. Also, the immediate availability of mismatched family member as a donor could have important financial implication as the considerable expenditure of additional typing and procurement of unrelated donor graft can be avoided.
Nonmyeloablative transplant: crossing HLA barriers
While the approach adopted by Aversa et al., 9 using the highly immunosuppressive and myeloablative conditioning regimen and a 'megadose' of extensively T cell-depleted G-CSF mobilized PBSC cells, has demonstrated encouraging survival results, it is not without limitations. First, the procedure is associated with significant regimen-related toxicity from the intensely myeloablative conditioning, and high treatment-related mortality (in the range between 35 and 40%) due to delayed immune recovery and infections. Second, a megadose of purified CD34 þ cells is crucial in overcoming the barrier of residual antidonor cytotoxic T-lymphocyte precursors in T-depleted mismatched transplant. There is continuing concern with regard to the slow engraftment, namely of platelets or graft failure, in patients receiving graft with lower cell dose. Previous studies from Tuebingen have shown delayed engraftment at CD34 doses less than 8 Â 10 6 /kg body weight. 13 As such, most physicians would usually target for 'megadose' of stem cell (410 Â 10 6 CD34 þ cells/kg body weight) from the donor while planning for haploidentical transplants, and this can place considerable demand on both the donors and the pheresis service for the following reasons: (i) The high graft content is easily achieved in children but can be a major obstacle in adults.
(ii) The immobility from long hours of pheresis can be exhausting for the donors and the procedure is often associated with significant pheresisrelated adverse effects. (iii) For the pheresis and stem cell processing laboratory staff, the procedures involved can be time-consuming and labor-intensive. However, even with high cell doses, graft failure in the range of 5-14% has been reported by other studies. [14] [15] [16] Communication from investigators and reports given at conferences on haploidentical transplantation have indicated that both graft failure and GVHD remained a problem and there were few survivors. 17 Developing new strategies of T-depletion or graft manipulation aiming at improved engraftment and a better tolerated, less toxic dose-reduced conditioning regimen, has become an important area of research.
Although the number of mismatched allogeneic transplant has increased steadily over the past few decades, this highrisk procedure can only be offered to a minority of patients, as most subjects are beyond the age where this approach involving the use of myeloablative preparative regimens can be performed within a reasonable degree of safety. GVHD, TRM and other toxicities remain significant and have limited use in otherwise healthy, relatively young patients. To extend allogeneic transplant to older patients and those with comorbidities, reduced-intensity or nonmyeloablative conditioning lacking such toxicities has been developed.
Results from Duke university
Rizzieri et al. 18 from Duke University recently reported one of the largest series of adult patients with nonmyeloablative transplant using 3-5/6 HLA-matched family donors. Fortynine patients with hematological malignancies or marrow failure were accrued. The patients in this group were, on average, older (median age of 48) than most other reported series of haploidentical transplantation. Using a nonmyeloablative preparative regimen consisting of fludarabine and cyclophosphamide in combination with alemtuzumab for in vivo and in vitro T cell depletion, the group reported successful engraftment in 94% of patients, low treatmentrelated mortality rates of 10.2% and severe GVHD of 8%. With more than half of patients not in first CR at transplantation, the high CR rate of 75% was encouraging. With 4.25 years of median follow-up, 1-year overall survival in this high-risk group was 31%. Subgroup analysis of 19 standard-risk patients showed 63% 1 year overall survival and 3-year median survival, which compared favorably with reports using alternative matched unrelated donors or cord blood. Despite the use of T-cell-depleting regimen, immune reconstitution analysis demonstrated encouraging evidence of quantitative lymphocyte recovery through the expansion of transplanted T cells by 3-6 months.
Results from Tuebingen/Dresden
Based on the promising experience gained at St Jude Children's Research Hospital (SJCRH), Memphis, in the pediatric population, 19, 20 investigators from Tuebingen explored a new T-cell depletion strategy in adult patients following dose-reduced conditioning. 21 Using this new approach, T-and B-cells (CD3/CD19) are negatively depleted from PBSC with 3.5-4 log T-depletion using anti-CD3-and anti-CD19-coated microbeads on a CliniMACS device. In contrast to the CD34 þ selection strategy pioneered by the Perugia group, CD3/CD19-depleted grafts harvested using this strategy not only contain CD34 þ stem cells but also ) and OKT-3 (5 mg/day, day À5 to þ 14) was used. Ten adult patients with a median age of 43 years and advanced hematological malignancies received mismatched transplant using this approach. Rapid engraftment with full donor chimerism was seen after 2 weeks in all patients. Six patients developed grade II GVHD and one developed lethal grade IV GVHD. Treatment-related mortality was 30% and overall survival was 50% with four patients in complete remission and median follow-up of 41 year. The fast engraftment seen in this CD3/CD19 group with CD34 doses as low as 5.2 Â 10 6 CD34 þ cells/kg demonstrates that successful haploidentical transplant may be feasible even without megadoses of CD34 þ stem cells. Importantly, the favorable immune reconstitution with fast reconstitution of NK cells was noted with this approach, resulting in fewer infectious complications in this group of patients.
In another recent study from Tuebingen, 22 Handgretinger et al. reported the outcome of 38 pediatric patients with high-risk hematological malignancies and severe aplastic anemia receiving haploidentical transplant using this approach. The dose-reduced conditioning was modified with fludarabine dose reduced (to reduce neurotoxicity) and OKT3 was omitted. Primary sustained engraftment occurred in 83% of patients and final engraftment was 98% when the remaining patients with graft failure had repeat transplant. Grade II-IV acute GVHD occurred in only 27% of patients. Overall TRM was low at 2.6%. The favorable event-free survival of 70% seen only in patients with nonmalignant disease and those in remission at time of transplant, suggests that disease relapse is a major obstacle among patients with refractory malignancies undergoing haploidentical transplant. Additional post-transplant cellular or humoral strategies for relapse prevention need to be evaluated.
Results from Massachusetts General Hospital
Based on murine models established by Sykes and coworkers, 23 a series of haploidentical stem cell transplantation has been conducted at Massachusetts General Hospital. To address the problems of graft failure and GVHD, the initial regimen has been modified to its current form, which includes cyclophosphamide, fludarabine, MEDI-507 (a monoclonal anti-CD2 antibody) and thymic irradiation. Mixed 'split lineage' lymphohematopoietic chimerism has been achieved in most cases with this strategy, with a predominance of donor myeloid chimerism and a much lower percentage of donor T-cell chimerism. In addition, mixed chimerism, including a low percentage of donor T-cell chimerism, can be successfully converted to full or nearly full donor chimerism with either no GVHD or manageable, primarily cutaneous GVHD. Recurrent malignancy and late infections have been the chief reasons for treatment failure with this approach. Efforts are underway to optimize the ex vivo T-cell depletion of the product and to explore different doses of delayed DLI.
24-26
Results from John Hopkins university O'Donnell et al. 27 from Johns Hopkins University have performed nonmyeloablative haploidentical transplant on 13 patients with hematological malignancies using low-dose TBI 2 Gy and fludarabine (with or without cyclophosphamide) as conditioning. High-dose post-transplant cyclophosphamide, given at 50 mg/kg on day 3, was added onto tacrolimus/mycophenolate mofetil to improve GVHD prophylaxis. Acute GVHD developed in 6 of the 13 patients. Six of the 13 patients were alive, 5 of whom were in complete remission at a median of 191 days posttransplant, including 2 patients with graft rejection. The results suggest possible benefits of pre-and posttransplantation cyclophosphamide in promoting engraftment and prevention of GVHD.
Results from Osaka university, Japan
Ogawa et al. 28 from Osaka University Hospital in Japan investigated the use of ATG-based nonmyeloablative conditioning regimen as previously reported by Slavin et al. 29 in the haploidentical transplant of 26 patients who had hematologic malignancies in an advanced stage or with poor prognosis. Using a conditioning consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and GVHD prophylaxis consisting of tacrolimus and methylprednisolone (1 mg/kg/day), 26 patients underwent transplantation using peripheral blood stem cells from 2 to 3 antigen HLA mismatched donors without T-cell depletion. All patients except for one achieved donor-type engraftment. Full donor was a chimerism achieved by day 14. Only five (25%) out of 20 evaluable patients developed grade II GVHD. Sixteen of the 26 patients are alive in complete remission. Four patients died of transplantation-related causes, and six died of progressive disease. The event-free survival at 3 years was 55%.
Results from Tokyo university, Japan
Kanda et al. 30 evaluated the feasibility of haploidentical unmanipulated peripheral blood stem cell transplantation from 2 or 3 loci-mismatched family member using in vivo alemtuzumab in 12 patients (median age 49.5 years) with high-risk hematological malignancies. Six patients received a TBI-based myeloablative regimen, whereas the remaining six patients older than 50 years received less intensive or nonmyeloablative fludarabine-based conditioning. Alemtuzumab was added on days À8 to À3 and CsP þ MTX were used as GVHD prophylaxis. There was no graft rejection, and the incidence of grade III-IV acute GVHD was only 9%. The nonrelapse mortality was observed in only 2 of 12 patients. None of the patients died of infectious causes despite impaired T cells immune reconstitution during the first 2 months after transplantation.
Conclusion
Haploidentical HSCT provides an opportunity for patients to benefit from HCT when an HLA genotypically matched sibling is not available. It presents a better logistic and practical alternative to matched unrelated donor transplantations. This may be especially important when dealing with a patient suffering from a disease with a rapid tempo where the urgency of transplant does not allow transplant from an unrelated donor to be organized, and also for non-Caucasian patients, in whom the chances of finding an unrelated match are still low, making the option of haploidentical transplant a more realistic prospect. Recent advances with effective T-cell depletion and reduced intensity conditioning have significantly decreased the early transplant-related mortality and GVHD, while enabling robust and prompt engraftment, and hence enhancing the therapeutic benefits of haploidentical transplantation. However, post-transplant infectious complications and relapse remain the most important barriers yet to be overcome, and new directions in the use of adoptive cellular immunity appear to be promising. Preliminary data have demonstrated the great potential of selective allodepletion in rapidly reconstituting immunity without GVHD. It appears that in some T cell-depleted haploidentical transplants, the given benefits of NK alloreactivity are expected to encourage the greater use of haploidentical transplants for a larger number of leukemia patients without matched donors. In addition, there are emerging data to suggest the use of NIMA-mismatched donors in providing an especially attractive strategy for patients who would not tolerate GVHD and prolonged immunosuppression. There are many issues that remain unresolved, including the role and timing of haploidentical SCT. The relative merits of a haploidentical family donor versus mismatched unrelated or umbilical cord blood donor remain to be defined, and it is hoped that a guideline will emerge from a large registry study. Current challenges are to improve our ability to identify those patients most likely to benefit from haploidentical transplantation, to better select donors, to develop transplant-conditioning regimens that are safer and more effective and to develop strategies that effectively eliminate GVHD while preserving antitumor and antimicrobial immunocompetence. In the meantime, ongoing translational research is very likely to improve this modality of treatment further.
